Adolor/GSK’s Entereg Approved By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Cleared at last, hospital constipation drug brings risk management plan.
You may also be interested in...
Adolor Faces R&D Setbacks, One With Entereg
Adolor discontinues development of alvimopan to treat chronic opioid bowel dysfunction after unsuccessful partnering discussions; it will proceed with the preclinical compound ADL7445.
Adolor Faces R&D Setbacks, One With Entereg
Adolor discontinues development of alvimopan to treat chronic opioid bowel dysfunction after unsuccessful partnering discussions; it will proceed with the preclinical compound ADL7445.
Adolor Seeks New Entereg Partner; Asks FDA To Weigh In On Chronic Use
GSK returns rights to alvimopan in outpatient settings; partnership continues for approved hospital use.